Suppr超能文献

常规临床实践中重度填塞2型Densiron 68:连续病例系列的解剖学和功能结果

Heavy tamponade 2 Densiron 68 in routine clinical practice: anatomical and functional outcomes of a consecutive case series.

作者信息

Stappler T, Heimann H, Wong D, Gibran S K, Groenewald C, Pearce I A

机构信息

St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.

出版信息

Eye (Lond). 2008 Oct;22(10):1360-5. doi: 10.1038/eye.2008.62. Epub 2008 Feb 29.

Abstract

PURPOSE

To evaluate the safety and efficacy of Densiron 68 in the clinical management of complex vitreoretinal cases with inferior retinal pathology.

METHODS

We present a prospective interventional non-comparative case series of 122 eyes of 121 consecutive patients. The primary end point was anatomical re-attachment of the retina, defined as retinal re-attachment in the absence of any tamponade agent. The secondary end point was to record the visual function and surgical complications. Inclusion criteria were proliferative vitreoretinopathy, posterior or inferior retinal breaks, and the patient's inability to posture.

RESULTS

Patients were 59.9 years (+/- 19.6), (m/f= 72:49), (R/L=65:57). Seventy-seven (63.1%) had previous unsuccessful retinal surgery and 45 had Densiron 68 at first procedure. The extent of the detachments was 2.21 quadrants (+/- 1.07) with macular involvement in 66 cases (54%). Eighty-seven (71.3%) patients achieved retinal re-attachment with one retinal operation and ultimately no tamponade, 102 (83.6%) achieved retinal re-attachment with more than one operation and ultimately no tamponade, and 112 (91.3%) patients achieved flat retina with tamponade in situ. Visual acuity rose from 1.38 LogMar (+/- 0.87) to 1.06 (+/- 0.83) (P=0.007). Densiron was removed after 135 days (+/- 73.2; range 35-405).

CONCLUSION

No tamponade agent can provide simultaneous support for the superior as well as the inferior retina; therefore, a tamponade agent that 'sinks' is a welcome new tool at the surgeon's disposal. The sequential use of heavy silicone oil followed by conventional silicone oil may be an acceptable management strategy in recurrent detachment.

摘要

目的

评估Densiron 68在伴有下方视网膜病变的复杂性玻璃体视网膜疾病临床治疗中的安全性和有效性。

方法

我们呈现了一个前瞻性干预性非对照病例系列,包含121例连续患者的122只眼。主要终点是视网膜的解剖复位,定义为在没有任何填塞剂的情况下视网膜复位。次要终点是记录视觉功能和手术并发症。纳入标准为增殖性玻璃体视网膜病变、视网膜后裂孔或下方裂孔,以及患者无法保持体位。

结果

患者年龄为59.9岁(±19.6),(男/女 = 72:49),(右眼/左眼 = 65:57)。77例(63.1%)曾有过视网膜手术失败,45例在首次手术时使用了Densiron 68。脱离范围为2.21个象限(±1.07),66例(54%)累及黄斑。87例(71.3%)患者通过一次视网膜手术实现视网膜复位且最终无需填塞,102例(83.6%)患者通过不止一次手术实现视网膜复位且最终无需填塞,112例(91.3%)患者在原位填塞的情况下视网膜变平。视力从1.38 LogMar(±0.87)提高到1.06(±0.83)(P = 0.007)。Densiron在135天(±73.2;范围35 - 405)后取出。

结论

没有一种填塞剂能够同时对上、下方视网膜提供支撑;因此,一种“下沉”的填塞剂是外科医生可利用的一种受欢迎的新工具。在复发性视网膜脱离中,先使用重硅油再使用传统硅油的序贯使用可能是一种可接受的治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验